JPMorgan Chase & Co. analysts give Fresenius Medical Care AG & Co. KGaA (ETR:FME) a ​​price target of €51.00

0

Fresenius Medical Care AG & Co. KGaA (ETR: FMEGet a rating) was assigned a price target of €51.00 ($54.26) by investment analysts at JPMorgan Chase & Co. in a research report released Wednesday, Borsen Zeitung reports. JPMorgan Chase & Co.The company’s price target would indicate a potential decline of 8.83% from the company’s current price.

A number of other equity analysts also weighed in on FME. Berenberg Bank set a price target of €82.20 ($87.45) on shares of Fresenius Medical Care AG & Co. KGaA in a research report on Tuesday. UBS Group set a price target of €75.00 ($79.79) on shares of Fresenius Medical Care AG & Co. KGaA in a Wednesday, May 11 research report. Stifel Nicolaus set a target price of €60.00 ($63.83) on shares of Fresenius Medical Care AG & Co. KGaA in a Friday, February 4 research report. Warburg Research set a target price of €62.00 ($65.96) on shares of Fresenius Medical Care AG & Co. KGaA in a research report on Tuesday, May 10. Finally, Deutsche Bank Rese… set a target price of €58.00 ($61.70) on shares of Fresenius Medical Care AG & Co. KGaA in a Thursday, May 5 research report.

ETR FME traded at €0.14 ($0.15) during Wednesday trading hours, reaching €55.94 ($59.51). 485,781 shares of the company were traded, compared to its average volume of 704,197. The company’s fifty-day moving average price is €59.92 and its two-hundred-day moving average price is 58. €24. The company has a current ratio of 1.10, a quick ratio of 0.76 and a debt ratio of 95.29. The company has a market capitalization of $16.39 billion and a P/E ratio of 16.91. Fresenius Medical Care AG & Co. KGaA has a 52-week minimum of €50.98 ($54.23) and a 52-week maximum of €71.14 ($75.68).

About Fresenius Medical Care AG & Co. KGaA (Get a rating)

Fresenius Medical Care AG & Co KGaA provides dialysis care and related dialysis care services in Germany, North America and abroad. It offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; equipment, training and patient support services including clinical monitoring, assisting with follow-up and arranging delivery of supplies to the patient’s home; and contracted dialysis services with hospitals in the United States for hospitalized patients with end-stage renal disease (ESRD) and for patients with acute renal failure.

Recommended Stories



Get news and reviews for Fresenius Medical Care AG & Co. KGaA Daily – Enter your email address below to receive a concise daily summary of breaking news and analyst ratings for Fresenius Medical Care AG & Co. KGaA and related companies with MarketBeat.com’s free daily email newsletter .

Share.

Comments are closed.